Mi Jeong Kim1,2,3, Chul-Hee Lee1,4, Youngeun Lee1,5, Hyewon Youn1,2,3,6, Keon Wook Kang1,2,4, JoonHo Kwon1,7, Abass Alavi8, Sean Carlin9, Gi Jeong Cheon1,2,5, June-Key Chung10,11,12,13,14. 1. Department of Nuclear Medicine, Seoul National University College of Medicine, Seoul, South Korea. 2. Laboratory of Molecular Imaging and Therapy, Cancer Research Institute, Seoul National University College of Medicine, Seoul, South Korea. 3. Tumor Microenvironment Global Core Research Center, Seoul National University, Seoul, South Korea. 4. Biomedical Sciences, Seoul National University College of Medicine, Seoul, South Korea. 5. Tumor Biology Program, Seoul National University College of Medicine, Seoul, South Korea. 6. Cancer Imaging Center, Seoul National University Cancer Hospital, Seoul, South Korea. 7. Institute of Radiation Medicine, Seoul National University College of Medicine, Seoul, South Korea. 8. Division of Nuclear Medicine, Department of Radiology, Hospital of the University of Pennsylvania, Philadelphia, PA, USA. Abass.Alavi@uphs.upenn.edu. 9. Division of Nuclear Medicine, Department of Radiology, Hospital of the University of Pennsylvania, Philadelphia, PA, USA. 10. Department of Nuclear Medicine, Seoul National University College of Medicine, Seoul, South Korea. jkchung@snu.ac.kr. 11. Laboratory of Molecular Imaging and Therapy, Cancer Research Institute, Seoul National University College of Medicine, Seoul, South Korea. jkchung@snu.ac.kr. 12. Tumor Microenvironment Global Core Research Center, Seoul National University, Seoul, South Korea. jkchung@snu.ac.kr. 13. Biomedical Sciences, Seoul National University College of Medicine, Seoul, South Korea. jkchung@snu.ac.kr. 14. Department of Nuclear Medicine, National Cancer Center, Goyang, Republic of Korea. jkchung@snu.ac.kr.
Abstract
PURPOSE: 2-Deoxy-2-[18F]fluoro-D-glucose ([18F]FDG) accumulation in inflammatory lesions can confound the diagnosis of cancer. In this study, we investigated [18F]FDG accumulation and efflux in relation to the genes and proteins involved in glucose metabolism in murine inflammation and cancer models. PROCEDURES: [18F]FDG accumulation and [18F]FDG efflux were measured in cancer cells (breast cancer, glioma, thyroid cancer, and hepatoma cells) and RAW 264.7 cells (macrophages) activated with lipopolysaccharide (LPS). The levels of mRNA expression were measured by real-time quantitative PCR (qPCR). The expression of glucose metabolism-related proteins was detected by western blotting. Dynamic [18F]FDG positron emission tomography-computed tomography (PET/CT) images were acquired for 2 h in tumor-bearing BALB/c nude mice and inflammatory mice induced by turpentine oil. RESULTS: [18F]FDG accumulation in MDA-MB-231 (breast cancer) increased with time, but that of HepG2 (hepatoma) reached a constant level after 120 min. [18F]FDG efflux in HepG2 was faster than that in MDA-MB-231. HepG2 strongly expressed glucose-6-phosphatase (G6Pase) compared with MDA-MB-231. [18F]FDG accumulation increased with time, and [18F]FDG efflux accelerated after the activation of RAW 264.7 cells. The expression levels of G6Pase, glucose transporter1 and glucose transporter3 (GLUT1 and GLUT3), and hexokinase II (HK II) increased after the activation of RAW 264.7 cells. [18F]FDG efflux in activated macrophages was faster than that in MDA-MB-231 cancer cells. MDA-MB-231 strongly expressed HK II protein compared with the activated RAW 264.7. In murine models, [18F]FDG accumulation in MDA-MB-231 cancer and inflammatory lesions increased with time, but that in HepG2 tumor increased until 20-30 min (SUVmeans ± SD (tumor/muscle), 3.0 ± 1.3) and then decreased (2.1 ± 0.9 at 110-120 min). CONCLUSIONS: There was no difference in the pattern of [18F]FDG accumulation with time in MDA-MB-231 tumors and inflammatory lesions. We found that [18F]FDG efflux accelerated in activated macrophages reflecting increased G6Pase expression after activation and lower expression of HK II protein than that in MDA-MB-231 cancer cells.
PURPOSE:2-Deoxy-2-[18F]fluoro-D-glucose ([18F]FDG) accumulation in inflammatory lesions can confound the diagnosis of cancer. In this study, we investigated [18F]FDG accumulation and efflux in relation to the genes and proteins involved in glucose metabolism in murineinflammation and cancer models. PROCEDURES: [18F]FDG accumulation and [18F]FDG efflux were measured in cancer cells (breast cancer, glioma, thyroid cancer, and hepatoma cells) and RAW 264.7 cells (macrophages) activated with lipopolysaccharide (LPS). The levels of mRNA expression were measured by real-time quantitative PCR (qPCR). The expression of glucose metabolism-related proteins was detected by western blotting. Dynamic [18F]FDG positron emission tomography-computed tomography (PET/CT) images were acquired for 2 h in tumor-bearing BALB/c nude mice and inflammatory mice induced by turpentine oil. RESULTS: [18F]FDG accumulation in MDA-MB-231 (breast cancer) increased with time, but that of HepG2 (hepatoma) reached a constant level after 120 min. [18F]FDG efflux in HepG2 was faster than that in MDA-MB-231. HepG2 strongly expressed glucose-6-phosphatase (G6Pase) compared with MDA-MB-231. [18F]FDG accumulation increased with time, and [18F]FDG efflux accelerated after the activation of RAW 264.7 cells. The expression levels of G6Pase, glucose transporter1 and glucose transporter3 (GLUT1 and GLUT3), and hexokinase II (HK II) increased after the activation of RAW 264.7 cells. [18F]FDG efflux in activated macrophages was faster than that in MDA-MB-231cancer cells. MDA-MB-231 strongly expressed HK II protein compared with the activated RAW 264.7. In murine models, [18F]FDG accumulation in MDA-MB-231cancer and inflammatory lesions increased with time, but that in HepG2tumor increased until 20-30 min (SUVmeans ± SD (tumor/muscle), 3.0 ± 1.3) and then decreased (2.1 ± 0.9 at 110-120 min). CONCLUSIONS: There was no difference in the pattern of [18F]FDG accumulation with time in MDA-MB-231tumors and inflammatory lesions. We found that [18F]FDG efflux accelerated in activated macrophages reflecting increased G6Pase expression after activation and lower expression of HK II protein than that in MDA-MB-231cancer cells.
Authors: R Airley; J Loncaster; S Davidson; M Bromley; S Roberts; A Patterson; R Hunter; I Stratford; C West Journal: Clin Cancer Res Date: 2001-04 Impact factor: 12.531
Authors: U Haberkorn; S I Ziegler; F Oberdorfer; H Trojan; D Haag; P Peschke; M R Berger; A Altmann; G van Kaick Journal: Nucl Med Biol Date: 1994-08 Impact factor: 2.408
Authors: H Zhuang; M Pourdehnad; E S Lambright; A J Yamamoto; M Lanuti; P Li; P D Mozley; M D Rossman; S M Albelda; A Alavi Journal: J Nucl Med Date: 2001-09 Impact factor: 10.057
Authors: Tolulope A Aweda; Zumrut F B Muftuler; Adriana V F Massicano; Dhruval Gadhia; Kelly A McCarthy; Stacy Queern; Anupam Bandyopadhyay; Jianmin Gao; Suzanne E Lapi Journal: Contrast Media Mol Imaging Date: 2019-10-29 Impact factor: 3.161